Issue of shares pursuant to Incentive Scheme
Updated : 13:01
Syncona Limited
Issue of shares pursuant to Incentive Scheme and PDMR dealings
9 July 2020
Syncona Limited (the "Company") today announces that a total of 914,880 new ordinary shares (representing 0.14% of the Company's existing issued ordinary shares) will be issued in satisfaction of realisations under the Company's long term Incentive Scheme. The new ordinary shares, when issued, will rank pari passu with the existing issued ordinary shares of the Company. In accordance with the rules of the Incentive Scheme, the number of ordinary shares to be issued has been calculated using the closing mid-market price on 8 July 2020, 257.5p.
In accordance with the rules of the Incentive Scheme, ordinary shares delivered on realisation may not be sold or transferred by the recipient for a period of one year following the realisation date.
The issue of shares include the following shares to be issued to senior members of the Syncona Investment Management Limited (SIML) leadership team:
Name | SIML Title | No. of shares to be issued |
Martin Murphy | Chief Executive Officer | 338,055 |
Chris Hollowood | Chief Investment Officer | 200,269 |
John Bradshaw | Chief Financial Officer | 56,219 |
Application has been made to the Financial Conduct Authority for the shares to be admitted to the Official List, and to the London Stock Exchange for the shares to be admitted to trading and it is expected that dealings will commence in the new ordinary shares on 15 July 2020.
Following admission, the Company will have 664,580,417 ordinary shares in issue and the total number of voting rights in the Company will be 664,580,417. The Company does not hold any ordinary shares in treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interests in, the Company under the FCA's Disclosure and Transparency Rules.
Notification of transactions by Persons Discharging Managerial Responsibilities ("PDMRs") are set out below.
[ENDS]
Enquiries
FTI Consulting
Ben Atwell / Natalie Garland-Collins
Tel: +44 (0) 20 3727 1000
Syncona Ltd
Siobhan Weaver / Annabel Clay
Tel : +44 (0) 20 3981 7940
Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com
About Syncona
Syncona is a leading FTSE250 healthcare company focused on founding, building and funding a portfolio of global leaders in life science. Our vision is to build a sustainable, diverse portfolio of 15 - 20 companies focused on delivering transformational treatments to patients in truly innovative areas of healthcare, through which we are seeking to deliver strong risk-adjusted returns for shareholders.
We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses. We take a long-term view, underpinned by a strategic capital base which provides us with control and flexibility over the management of our portfolio. We focus on delivering dramatic efficacy for patients in areas of high unmet need.
1. | Details of PDMR / person closely associated with them ("PCA") | |||||
a) | Name | Martin Murphy | ||||
b) | Position / status | Chief Executive Officer, SIML | ||||
c) | Initial notification / amendment | Initial Notification | ||||
2. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument | Ordinary shares GG00B8P59C08 | ||||
b) | Nature of the transaction | Issue of shares pursuant to the Syncona long term Incentive Scheme | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price |
N/A | ||||
e) | Date of the transaction | 9 July 2020 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
g) | Currency | GBP - British Pound |
1. | Details of PDMR / person closely associated with them ("PCA") | |||||
a) | Name | Chris Hollowood | ||||
b) | Position / status | Chief Investment Officer, SIML | ||||
c) | Initial notification / amendment | Initial Notification | ||||
2. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument | Ordinary shares GG00B8P59C08 | ||||
b) | Nature of the transaction | Issue of shares pursuant to the Syncona long term Incentive Scheme | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price |
N/A | ||||
e) | Date of the transaction | 9 July 2020 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
g) | Currency | GBP - British Pound |
1. | Details of PDMR / person closely associated with them ("PCA") | |||||
a) | Name | John Bradshaw | ||||
b) | Position / status | Chief Financial Officer, SIML | ||||
c) | Initial notification / amendment | Initial Notification | ||||
2. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument | Ordinary shares GG00B8P59C08 | ||||
b) | Nature of the transaction | Issue of shares pursuant to the Syncona long term Incentive Scheme | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price |
N/A | ||||
e) | Date of the transaction | 9 July 2020 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
g) | Currency | GBP - British Pound |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.